SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as the community rallies around its position as a Bitcoin-native meme coin within the burgeoning Rune ecosystem. Discussions highlight the strong community, fair distribution, and the potential for $DOG to bridge Bitcoin culture with broader markets through its association with $CBLO. The community emphasizes holding through market volatility.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as traders discuss its potential as a privacy-focused alternative to Bitcoin, drawing comparisons to early BTC gains. Community members are pointing to recent investments from figures like the Winklevoss twins, as well as speculation around institutional adoption and regulatory environments favoring privacy coins. Some traders believe ZEC is inversely correlated to Bitcoin and are closely watching technical patterns for potential breakouts.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as the community discusses potential catalysts including a Wells Fargo upgrade, the possibility of Trump-era tariffs being overturned by the Supreme Court, and a potential boost from a collaboration with SKIMS. Some traders are pointing to technical indicators suggesting a potential breakout, while others express concerns about the company's performance and valuation. Speculation around an upcoming earnings report is also contributing to the heightened interest.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia (JMIA) is trending amid discussions about its Q3 earnings, long-term financial targets presented at its investor day, and a recent fund filing revealing a significant stake. Community members are focused on the company's potential for growth in the African market, its path to profitability, and potential short squeeze opportunities. Bullish sentiment appears to be building around JMIA's position as an uncorrelated asset and its long-term prospects in a growing market.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

TENX is trending as investors discuss its strong cash position, low share float, and Phase 3 trials targeting a significant patient population. The community is highlighting the potential for a squeeze, drawing comparisons to other stocks with similar ownership structures and catalysts. Some are noting potential institutional interest.

Memecoin on Injective taken over by the community.

Nonja

$NONJA is trending as the community rallies around its strong performance within the Injective ecosystem and its unique attributes such as high burned liquidity and a dedicated community. Bullish sentiment is fueled by the anticipation of Injective's growth, with potential ETFs and significant capital inflows expected to further boost $NONJA, which many see as a leveraged play on $INJ. The community is actively discussing its NFT collections and anticipating substantial gains as the broader market turns optimistic.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending as investors weigh recent sales data and analyst ratings, with the community debating its short-term direction. Some traders are eyeing potential wedge setups and range-bound trading opportunities, while others are focused on the company's robust membership model and long-term growth prospects. Discussions also include the potential impact of economic factors and upcoming sales reports.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen ($SG) is trending as investors assess recent insider buying by the CEO and potential for a short squeeze, given the stock's significant drop from previous highs. The community is weighing the company's valuation relative to sales and discussing its potential as a turnaround story or acquisition target in the competitive fast-casual dining sector. Discussions also involve the company's AI and robotics initiatives and their impact on future profitability.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

LLY is trending as community members discuss its potential leadership in the obesity market due to strong sales and EPS growth, driven by drugs like Mounjaro. Despite a high RSI suggesting it may be overbought, some traders anticipate the stock will reach $1100, while others discuss potential pullbacks and entry points.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

TMUS is trending as the community discusses its recent price action in relation to technical indicators and analyst ratings, with some seeing a potential buying opportunity. Discussions also involve potential partnerships and competition within the telecom sector, especially with the launch of new services. Upcoming earnings are a key focus for many traders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Has Strong Estimate for ALLO FY2025 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - HC Wainwright upped their FY2025 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a report released on Monday...

Allogene Therapeutics (NASDAQ:ALLO) Issues Earnings Results, Beats Expectations By $0.04 EPS

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus...

Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales

ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.

TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals

Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.

Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain 

ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.

CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza

Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data

Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure

KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.

AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study

AZN's baxdrostat hit the main goal in the phase III Bax24 study, showing significant blood pressure reductions in patients with resistant hypertension.

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Allogene Therapeutics Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.22	--	--	N/A
Q3 '25	-$0.22	-$0.19	13.95%	BEAT
Q2 '25	-$0.27	-$0.23	14.07%	BEAT
Q1 '25	-$0.29	-$0.28	3.60%	BEAT
Q4 '24	-$0.33	-$0.28	14.25%	BEAT

ALLO
Allogene Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest ALLO News

ALLOAllogene Therapeutics Inc